DCF Valuation
Recursion Pharmaceuticals Inc (RXRX) DCF Valuation — Is RXRX overvalued?
The estimated DCF fair value of one Recursion Pharmaceuticals Inc (RXRX) share is $0.76. Compared to the current market price of $3.17, the stock is overvalued by 75.9%.
DCF fair value
$0.76
Market price
$3.17
Upside / downside
−75.9%
Recursion Pharmaceuticals Inc (RXRX) DCF valuation FAQ
What is the DCF fair value of Recursion Pharmaceuticals Inc (RXRX)?
The discounted-cash-flow model estimates the intrinsic fair value of one Recursion Pharmaceuticals Inc (RXRX) share at $0.76, based on a 10-year projection of its cash flows converging to Damodaran industry averages.
Is Recursion Pharmaceuticals Inc (RXRX) overvalued or undervalued?
Against the current market price of $3.17, the DCF fair value of $0.76 implies RXRX is overvalued by 75.9%.
How is the RXRX DCF value calculated?
It is a 10-year discounted-cash-flow estimate built from Recursion Pharmaceuticals Inc's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when Recursion Pharmaceuticals Inc files a new quarterly or annual report.
How this RXRX valuation is built
The model projects ten years of Recursion Pharmaceuticals Inc's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing Recursion Pharmaceuticals Inc's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.
WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.
The market price refreshes daily; the DCF fair value updates when Recursion Pharmaceuticals Inc files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-06.